The association between uric acid (UA) and cardio‐metabolic conditions has been recognized for a long time. However, recently, a body of evidence has highlighted the independent role of UA in a series of conditions, including renal and cardiovascular diseases. In this light, data regarding the prognostic role of UA in acute coronary syndrome (ACS) is scarce. A total of 300 patients presenting with ACS and meeting the inclusion criteria will be enrolled. The sample size is feasible as the Department of General Medicine, SAIMS Hospital-Indore, sees more than 100 newly diagnosed and existing chronic heart disease patients annually. In a study involving 300 patients, the distribution of normouricaemic and hyperuricaemic individuals was analyzed based on gender, smoking, and alcohol consumption. Among the participants, 39% were female, with 34.2% being normouricaemic and 43.8% hyperuricaemic. Males constituted 61% of the study group, with 65.8% being normouricaemic and 56.2% hyperuricaemic. Regarding lifestyle factors, 45.9% of the total participants were smokers, with 45.2% in the normouricaemic group and 46.6% in the hyperuricaemic group. The majority of patients in the normouricaemic group had an uneventful hospital stay and recovered earlier compared to those in the hyperuricaemic group, who experienced a longer duration of hospitalisation and higher incidences of complications. In conclusion, serum uric acid level, an inexpensive and readily accessible biomarker, may serve as an effective predictor for future adverse events related to acute coronary syndrome (ACS).